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Abstract The drugs of abuse cocaine (C), heroin (H), and
morphine (M) have been studied to enable understanding of the
occurrence of cocaine–opioid interactions at a molecular level.
Electrochemical, Raman, and NMR studies of the free drugs
and their mixtures were used to study drug–drug interactions.
The results were analyzed using data obtained from quantum-
mechanical calculations. For the cocaine–morphine mixture
(C–MH), formation of a binary complex was detected; this
involved the 3-phenolic group and the heterocyclic oxygen of
morphine and the carbonyl oxygen and the methyl protons of
cocaine’s methyl ester group. NMR studies conducted simul-
taneously also revealed C–MH binding geometry consistent
with theoretical predictions and with electrochemical and
vibrational spectroscopy results. These results provide evi-
dence for the occurrence of a cocaine–morphine interaction,
both in the solid state and in solution, particularly for the
hydrochloride form. A slight interaction, in solution, was also
detected by NMR for the cocaine–heroin mixture.
Keywords Cocaine . Opioids . Drug–drug interaction .
Electrochemistry .Molecular spectroscopy
Introduction
Drug abuse is a serious health problem in our society and is
currently one of the greatest concerns of governments. Of
particular interest is the increase in the number of drug
addicts who report combined abuse of cocaine (C) and the
opioid agonist heroin (H) (“speedball”) [1, 2]. Apart from
the harsher effects of cocaine [1, 3], this drug combination
has been reported to cause a more pleasurable or rewarding
experience than cocaine or heroin alone [3–6]. This enhanced
effect may contribute to the reduced motivation of “speed-
ball” users to stop their drug habit, and their greater
probability of relapse compared with single drug users. Al-
though the underlying biological basis for abuse of cocaine
and opioid combinations is unclear, controlled clinical studies
give insight into the desire for dual abuse of these substances.
Several drug-discrimination procedures have been used
extensively to characterize the pharmacological mecha-
nisms of action that mediate the abuse-related effects of
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cocaine and mu opioids, either alone or in mixtures [1, 3,
7–17]. The objective of these studies was evaluation of the
hypothesis that cocaine and mu agonists potentiate each
other’s discriminative stimulus (DS). The results of the
studies have been contradictory, however, and in many
instances results have varied for subjects within a study.
Polettini et al. [18] have suggested the occurrence of a
pharmacodynamic interaction between heroin and cocaine,
but this has not been confirmed owing to the paucity of data
and the many uncontrolled variables involved.
Human laboratory studies have enabled determination of
the acute subjective and physiological effects of cocaine in
combination with opioid mu agonists [2, 19, 20]. The
subjective effects of different dose combinations of mu
agonists and cocaine were found to be greater than those of
either drug alone. The qualitative profile of such effects
produced by the opioid–cocaine combination was found to
be approximately equivalent to the sum of effects produced
by the two drugs separately, rather than to novel and unique
subjective effects [2, 3, 15, 16].
Although numerous biological studies of the subject have
been reported, no conclusive data on drug–drug interactions is
yet available in the literature [2, 14, 21–23]. Electrochemical
investigation of the mechanisms of oxidation of cocaine,
heroin, morphine, and several metabolites [24–26] led,
however, to the observation of curious chemical behavior
when cocaine and opioids (heroin and its metabolite
morphine (M)) were combined in solution. These findings,
and the lack of chemical data supporting the interpretation of
this particular behavior (either in pure solution or in
biological systems), prompted the authors to conduct a more
thorough study. Consequently, detailed electrochemical and
spectroscopic studies (both Raman and multidimensional
NMR) were performed on cocaine (C), heroin (H), and
morphine (M), and on 1:1 C–H and C–M mixtures both in
the solid state and in solution (Fig. 1a). Complete confor-
mational analysis (both geometry optimization and frequen-
cy calculations) was also conducted on cocaine and on the
opioids heroin and morphine by quantum mechanical
calculations (at the density functional theory (DFT) level)
to enable a better understanding of their structural behavior
at a molecular level, thus aiding interpretation of the
electrochemical and spectroscopic experimental data.
Experimental
Apparatus
Electrochemical studies
Electrochemical studies were performed using an Autolab
PGSTAT 12 potentiostat/galvanostat (EcoChemie, Nether-
lands) and a one-compartment glass electrochemical cell.
Voltammetric curves were recorded at room temperature
using a three-electrode system. A glassy carbon working
electrode (GCE) (d=2 mm), a platinum wire counter-
electrode, and an Ag/AgCl saturated KCl reference elec-
trode were used. A Crison (Spain) pH-meter with glass
electrode was used for pH measurement.
DFT calculations
Quantum mechanical calculations—full geometry optimiza-
tion and calculation of the harmonic vibrational frequencies—
were performed using the Gaussian 98W program [27],
within the density functional theory (DFT) approach, to
account properly for electron correlation effects. The widely
employed hybrid method denoted by B3LYP [28, 29], which
includes a mixture of HF and DFT exchange terms and the
gradient-corrected correlation functional of Lee, Yang, and
Parr [30, 31], as proposed and parameterized by Becke [32,
33], was used, with the double-zeta split valence basis sets 6-
31G* [34] and 6-31G** [35]. Molecular geometries were
fully optimized (bond lengths to within ca 0.1 pm and bond
angles to within ca 0.1°) by use of the Berny algorithm,
using redundant internal coordinates [36]. The final root-
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Fig. 1 (a) Schematic representation of morphine, cocaine and heroin
and (b) differential pulse voltammograms obtained from 100 μmol
L−1 solutions of morphine (unbroken line), cocaine (dashed line), and
heroin (dotted line). (pH 7, 0.2 mol L−1 phosphate buffer, scan rate
5 mV s−1, pulse amplitude 50 mV, pulse width 20 ms)
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mean-square (rms) gradients were always less than 3×10−4
hartree bohr−1 or hartree radian−1. No geometric constraints
were imposed on the molecules under study. All frequency
calculations were run at the B3LYP/6-31G* level and
wavenumbers above 400 cm−1 were scaled [37] before
comparing them with the experimental data.
Raman spectroscopy
The Raman spectra of the solid samples, at 20 °C, were
recorded on a triple-monochromator Jobin–Yvon T64000
Raman system (0.640 m, f/7.5) with holographic gratings of
1,800 grooves mm−1. The premonochromator stage was
used in the subtractive mode. The detection system was a
non-intensified CCD (charge-coupled device). The
514.5 nm line of an argon laser (Coherent, model Innova
300) was used as excitation radiation, providing ca 80 mW
at the sample position, and a 90° geometry was used. The
entrance slit was set to 200 μm and the slit between the
premonochromator and the spectrograph was opened to
13.2 mm. An integration time of 5 s and 20 to 30 scans
were used in all the experiments. Samples were sealed in
Kimax glass capillary tubes with an inner diameter of
0.8 mm. Under these conditions the error in wavenumbers
was estimated to be within 1 cm−1.
NMR spectroscopy
1H-and 13C NMR (1H decoupled) spectra were acquired, at
room temperature, on a Bruker Avance 300 spectrometer
operating at 300.13 and 75.47 MHz, respectively. Chemical
shifts are expressed as δ (ppm) values relative to tetrameth-
ylsilane (TMS), used as internal reference, and coupling
constants (J) are given in Hertz (Hz). CD3OD was used as
the sample solvent. Unequivocal 1H assignments were made
by using 2D gCOSY and NOESY (800-ms mixing time)
experiments, and 13C assignments were made with the aid
of 13C NMR DEPT and 2D gHSQC and gHMBC experi-
ments (delays for one bond and long-range J C/H couplings
having been optimized for 145 and 7 Hz, respectively).
Reagents and solutions
Morphine free base (M) and morphine hydrochloride (MH)
were obtained from Uquipa (Lisbon, Portugal) and were
used without further purification. Cocaine hydrochloride
was kindly supplied by Policia Judiciária (Lisbon, Portu-
gal). Heroin hydrochloride was synthesized as described
elsewhere [25]. All other chemicals and solvents were
reagent grade and were used as received. Deionized water
(conductivity less than 0.1 μS cm−1) was used throughout.
The pH 7 phosphate buffer used for voltammetric de-
terminations was prepared by mixing 40.5 mL 0.2 mol L−1
dipotassium hydrogen phosphate and 9.5 mL 0.2 mol L−1
potassium dihydrogen phosphate and diluting to 100 mL.
NMR studies were performed on solutions containing
equal concentrations (0.1 mol L−1) of either single drugs or
mixtures.
Results and discussion
Electrochemical studies
The electrochemical oxidation behavior of cocaine and the
two opioids heroin and its main metabolite morphine
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Fig. 2 (a) 3D plot and (b) plot of Ip against concentration obtained
from successive differential pulse voltammograms (I, phenolic anodic
oxidation peak; II, tertiary amine anodic oxidation peak), for cocaine
at concentrations of 0.0, 50.0, 60.3, 70.2, 80.2, and 90.0 μmol L−1 and mor-
phine at a concentration of 60 μmol L−1 (pH 7, 0.2 mol L−1 phosphate
buffer, scan rate 5 mV s−1, pulse amplitude 50 mV, pulse width 20 ms)
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Fig. 3 (a) Schematic represen-
tation of the calculated (B3LYP/
6-31G**) lowest-energy confor-
mations for cocaine (C), heroin
(H), and morphine (MH) salts,
and (b) main conformational
differences between morphine
base (M) and N-protonated
(MH) morphine
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(Fig. 1b) was studied at physiological pH at a glassy carbon
electrode using differential pulse voltammetry. The study
showed that anodic oxidation of both the phenolic (Ep=
+0.42 V) and tertiary amine (Ep=+1.0 V) groups was
possible for morphine whereas oxidation of the tertiary
amine group, only, is possible for cocaine (Ep=+1.0 V) and
heroin (Ep=+0.9 V) (Fig. 1b) [25, 26].
To gain insight into the molecular oxidative mechanisms
of the drugs under study the electrochemical behavior of
binary mixtures was also investigated.
Cocaine and heroin each have only one oxidation peak,
corresponding to oxidation of the tertiary amine group
present in both molecules; this occurs at very similar
potentials, meaning that electrochemical study of the
cocaine–heroin interaction is not possible because of
convolution of the peaks. Because study of the cocaine–
opioid interaction by use of voltammetric methods depends
on the ability to measure the oxidation potentials of each
compound separately only the cocaine–morphine mixture
can be investigated. Considering the described pharmaco-
logical effects, this mixture was also studied.
To study the cocaine–morphine interaction the following
experimental procedure was used. First, standard calibration
plots were obtained for each drug separately (no significant
adsorption processes were observed). Second, using the
standard addition method the cocaine–morphine mixture
was studied by fixing the concentration of morphine and
adding cocaine (Fig. 2a). The results obtained were
surprising because they showed a marked interaction
between the two drugs.
When the concentration ofmorphinewas fixed, the peak for
the oxidation of the phenolic group ofmorphine (Ep=+0.42 V)
unexpectedly decreased as the concentration of cocaine was
increased (Fig. 2b). Considering the dilution effect as
negligible, this peak current should have remained constant.
From study of the cocaine–morphine mixture (hydro-
chloride salts; C–MH) important conclusions can be drawn.
The results obtained clearly suggest that a strong interaction
Fig. 4 Schematic representation
of the model proposed for the
cocaine–morphine salt (C–MH)
interaction (structures calculated
at the B3LYP/6-31G** level)
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occurs between these two drugs in solution, with formation
of a complex or adduct. The chemical integrity of each drug
seems to be intact in the C–MH mixture, because, apart
from the intensity change, no significant changes in the
peak potential of the oxidation waves was observed. To
clarify the cocaine–morphine interaction further a detailed
study was conducted, both in the solid state and in solution,
using theoretical methods coupled with spectroscopic
techniques (Raman and NMR).
DFT Calculations
Quantum mechanical calculations at the density functional
theory (DFT) level were performed for the molecules under
study—morphine (both basic (M) and N-protonated (MH)
species), heroin, and cocaine (protonated species)—and for
the 1:1 (w/w) mixtures C–H, C–M, and C–MH. These
calculations enabled determination of the conformational
preferences of the drugs (i.e. the sites at which intermolec-
ular interactions may occur), thus leading to a better
understanding of the cocaine–opioid close contacts detected
experimentally.
The lowest-energy conformations calculated for cocaine,
heroin, and morphine (in their N-protonated forms) are
depicted in Fig. 3a. The conformational differences be-
tween the basic and hydrochloride forms of morphine were
also evaluated. It was found that N-protonation of this
molecule leads to a slightly more open molecular confor-
mation (Fig. 3b), which will probably favor interaction of
this opioid with cocaine. The three-dimensional structures
obtained also enabled identification of the steric and
electrostatic constraints within each molecule and the
geometrical requirements for intermolecular interactions.
Different possible modes of interaction of cocaine with
either morphine or heroin were investigated. From these
results it was verified that the presence of the two terminal
–O(C=O)CH3 groups in heroin probably hamper docking
of the cocaine molecule whereas the approach to the
morphine cavity defined by the two aromatic rings was
found to be more favorable, because it does not involve any
significant steric hindrance (Fig. 4). Theoretical calcula-
tions performed for the C–H and C–M systems yield
shorter distances between the two components of the
mixture for the latter, especially for protonated species
(C–MH) (Table 1).
Table 1 Most significant conformational changes detected for
morphine hydrochloride (MH) on formation of the cocaine–morphine
binary complex (C–MH) (Fig. 4) (atoms are numbered in accordance
with Fig. 4; atoms from cocaine are represented in bold)
Bond lengths (pm) C–MH MH
(C=)O23–H20 247.0 –
(O)C21H25–O28 205.0 –
Bond angles (degrees)
C34–N–C35 114.7 115.5
C31–N–C35 117.7 119.9
N–C34–C33 117.5 115.9
C3–C4–O28 127.0 125.6
C6–C5–O28 126.7 125.4
C5–C6–O17 115.0 116.9
C4–C3–O18 120.0 119.0
Dihedral angles (degrees)
C35–N–C34–C33 133.3 138.4
C35–N–C31–C32 84.8 85.8
C35–N–C31–C30 –67.2 –70.6
N–C34–C33–C29 –31.6 –32.2
C30–C29–C5–O28 132.0 128.1
O17–C6–C5–O28 23.0 24.9
O18–C3–C4–O28 –16.2 –13.4
250 500 750 1000 1250 1500 17500
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C:H 
MH 
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C:MH
C 
Fig. 5 Experimental Raman spectra (50–1750 cm−1, solid state, at
20 °C) obtained for cocaine (C), morphine (MH), and heroin (H) salts,
and for the 1:1 mixtures C–MH and C–H (arrows mark the most
significant changes in the spectra)
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Spectroscopic studies
Raman spectroscopy
Solid-state Raman spectra were recorded for morphine
(both the basic (M) and N-protonated (MH) forms), heroin,
and cocaine (protonated species), and for 1:1 (w/w)
cocaine–heroin (C–H) and cocaine–morphine (C–M and
C–MH) mixtures (Figs. 5 and 6), to check for the
occurrence of the cocaine–opioid close contacts detected
by electrochemical methods. These experiments were
coupled with theoretical calculations which yielded the
conformational preferences of the molecules under study,
including possible sites of intermolecular interaction(s).
The vibrational pattern obtained for the C–M, C–MH,
and C–H mixtures reflect a clear interaction occurring
between cocaine and morphine, but not between cocaine
and heroin. A noticeable interaction was detected for the
former, particularly for the morphine salt (Figs. 5 and 6).
For the C–H sample no variations in the Raman bands were
observed (in either the low or high-frequency regions)
compared with the individual molecules (Figs. 5 and 6),
even one week after preparation of the mixture.
For the C–MH sample, however, clear changes, compared
with the Raman bands of the free components, were detected
immediately after mixing the two drugs. In the 50 to
1750 cm−1 range (which includes the CH2, C=C and C–O
deformation modes, Fig. 5), the Raman pattern of morphine,
especially the bands at 632, 775, 1066, 1347, 1419, and
1635 cm−1, was found to be strongly affected by the
presence of cocaine. In the high-wavenumber region (which
contains the CH-stretching modes, Fig. 6) new features were
observed for the mixture, at 2959, 3019, 3052, and
3138 cm−1 whereas the bands at 2841 and 2877 cm−1 from
cocaine and at 2998 and 3000 cm−1 from morphine either
disappeared or decreased markedly in intensity. The most
affected bands were, therefore, those ascribed to the aromatic
(oxygen-containing) moiety of the morphine molecule, i.e.
the ν(C=C)ring (1635 cm
−1) and ν(CH/CH2)ring (ca 2900 to
3100 cm−1) modes. This Raman pattern did not change on
aging of the sample.
These experimental findings were corroborated by the
theoretical calculations performed for the morphine base
and hydrochloride species. Indeed, both the Raman and
electrochemical data obtained for the C–MH mixture are
readily explained if the interplay between the two mole-
cules is proposed to occur predominantly through the inner
cavity of the morphine, possibly via C=O23 ... H20(O) and
(C)H25 ... O28 interactions (Fig. 4), which are favored by
the N-protonation process because of the larger dimensions
of the nitrogen-containing ring in this acidic form (Fig. 3b).
Relevant experimental and calculated vibrational wave-
numbers for cocaine (C), morphine hydrochloride (MH)
and the C–MH (1:1) mixture, and tentative assignment of
these characteristic bands, are listed in Table 2.
Nuclear magnetic resonance spectroscopy
In the NMR study of the interactions between cocaine and
the opioids morphine and heroin complete and unambigu-
ous characterization of the drugs, alone or in 1:1 mixtures,
was achieved by both 1D and 2D NMR experiments in
CD3OD solution.
1H unequivocal assignments were
Wavenumber (cm-1) 
32002800 3000
MH 
C:MH
C 
H 
C:H 
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Fig. 6 Experimental Raman spectra (2800–3200 cm−1, solid state, at
20 °C) obtained for cocaine (C), morphine (MH) and heroin (H) salts,
and for the 1:1 mixtures C–MH and C:H (arrows mark the most
significant changes in the spectra)
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achieved by use of 2D-gCOSY and NOESY and 13C
assignments were achieved by use of 13C NMR DEPT
and 2D-gHSQC and gHMBC experiments. Because the
most significant shift variations were observed for the
carbon atoms, the results from the 13C NMR spectra were
tabulated for correlation of the data (Table 3).
Analysis of the 13C NMR spectra of cocaine (C),
morphine (M), heroin (H), and the 1:1 (w/w) C–M and C–H
mixtures revealed coherent chemical shift variations for the
opioid and cocaine carbon resonances (Table 3). These
variations suggest interaction of cocaine with the opioid
molecules essentially through the nitrogen lone-pair elec-
trons of the latter and the methyl ester carbonyl carbon of
cocaine. This can be concluded from the deshielding effect
detected for the C9, C10, and C16 atoms (Δδ=−0.3 to
−0.8 ppm) of the opioid molecule on complexation, and
from the shielding of the carbon atoms of the methyl ester of
cocaine (Δδ=+0.5 to 0.8 ppm). This drug–drug interaction
implies:
1. steric hindrance involving the N-methyl group of
cocaine, which is the responsible for the shielding
effect on its C5 atom; and
2. formation of van der Waals interactions between
cocaine and each of the opioid molecules, possible
affecting their conformational geometries.
This conformational rearrangement is probably respon-
sible for some of the shielding effects observed for the C8,
C11, C12, C13, and C14 atoms of the opioid molecules
(Δδ=+0.5 to 1.5 ppm), and for the deshielding detected for
several carbon atoms of cocaine (Δδ=−0.4 to 1.5 ppm).
Table 2 Experimental and calculated Raman wavenumbers for the most stable conformers of cocaine (C), morphine hydrochloride (MH), and the
1:1 (w/w) cocaine–morphine mixture (C–MH)
C MH C–MH Approximate descriptiona
Exp. Calc.b Exp. Calc.b Exp.
632 630 613c ν(CO) + ν(CC) + Γ(CC) (aromatic rings)
775 774 786 γ(CH) (aromatic rings)
1066 1109 1060c ν(CO) + ν(CC) (aromatic ring)
1347 1399 1312c δ(OH) + δ(CH) + ν(C=C)
1419 1401 1452c δ(OH) + ν(C=C) (aromatic rings)
1635 1621 1629c ν(C=C) (aromatic rings)
2841 2917 — νs(NCH3)
2877 2948 2886c ν(CH/CH2) (cycloheptane)
2972 2970 2959 ν(CH2) (non-aromatic rings)
2998 2986 2992c ν(CH2) (non-aromatic rings)
3000 2995 2997c ν(CH2) (non-aromatic rings)
3025 3030 3019 ν(CH) (aromatic rings)
3068 3065 3052 νas(OCH3)
3120 3085 3138 ν(CH) (aromatic rings)
a δ, in-plane deformation; γ, Γ, out-of-plane deformations; ν, stretching (s, symmetric; as, anti-symmetric)
b B3LYP/6-31G* level of calculation; frequencies scaled by 0.9614 [39]
c Displays a marked intensity decrease relative to the free C or MH bands
Table 3 Most significant NMR chemical shift variations (Δδ, ppm)
observed for the opioid (heroin and morphine) and cocaine carbon
atoms (atoms are numbered in accordance with Fig. 1)
Δδ C–M Δδ C–MH Δδ C–H Carbon atoms
Opioid
1.33 −2.12 0.61 C8
−0.72 1.22 −0.10 C7
−0.79 1.38 −0.56 C9
−0.76 0.01 −0.53 C10
1.47 −2.30 0.56 C11
0.73 −1.15 0.58 C12
0.46 −0.43 0.46 C13
1.07 −0.31 0.87 C14
1.15 −0.83 0.89 C15
−0.26 −4.49 −0.21 C16
0.63 −0.70 0.47 NCH3
Cocaine
−0.67 −0.71 −0.49 NCH3
−0.49 −0.49 −0.42 C1
0.70 0.73 0.51 C5
−0.93 −0.99 −0.61 C3
−1.47 −1.54 −1.05 C2
−0.93 −0.98 −0.69 C4
−0.51 −0.54 −0.38 CH26
−0.82 −0.86 −0.60 CH27
0.72 0.75 0.53 COOCH3
−0.34 −0.36 −0.24 ArCO
−0.35 −0.37 −0.26 C1’
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A completely different situation was encountered for
morphine hydrochloride (MH). The 13C NMR peaks
recorded for the C10, C13, C14, C15, C16, and N-CH3 atoms
are broad and of low intensity, suggesting significant
mobility and flexibility of this part of the molecule. After
addition of cocaine, this mobility is found to be restrained,
because the signals of these carbon atoms become narrow
and more intense. Because morphine is N-protonated, the
C–MH interaction cannot occur through morphine’s nitro-
gen atom. This conclusion is also supported by the most
important shift variations obtained for the C–MH mixture
compared with those for the C–M system (Table 3). The Δδ
values obtained for the cocaine–morphine hydrochloride
mixture suggest the formation of a bidentate complex, via
interactions between the carbonyl oxygen atom of the
cocaine methyl ester and the 3-hydroxyl group of mor-
phine, and between the methyl protons of the cocaine
methyl ester and the heterocyclic oxygen of morphine
(Fig. 4). This interplay leads to a strong deshielding effect
on the C11 and C12 carbon atoms (Δδ=−1.2 to −2.3 ppm)
and to a constrained conformation of the “flexible arm” of
cocaine (as discussed above). This may be responsible for a
significant steric hindrance between C16 and C8 which is
responsible for the marked deshielding effect observed for
these atoms (Δδ=−2.1 to −4.5 ppm) and for the shielding
of C7 and C9 (Δδ=+1.3 to 1.4 ppm). These effects are found
to be propagated to the neighboring carbons atoms (Table 3).
Conclusion
Spectroscopic (Raman and NMR) and electrochemical
techniques, coupled with DFT theoretical methods (yield-
ing a complete conformational analysis), have been shown
to be powerful tools for understanding the intermolecular
interactions associated with co-abuse of drugs.
Overall, the results presented provide clear evidence of
the occurrence of a cocaine–morphine interaction, both in
the solid state and in solution, particularly for the hydro-
chloride form of morphine. A slight interaction, in solution,
between cocaine and heroin was also detected by NMR.
It is important to mention that a cocaine–morphine
combination such as that described in this study can also
occur with heroin in vivo (e.g. after “speedball” intake),
because heroin has ester bonds that are described as quite un-
stable, both in vitro and in vivo. Because heroin has a very
short half-life (2 to 5 min), it is widely believed it acts mainly
through its more stable agonistic metabolites [40–43]. It is
well established that this semi-synthetic drug suffers rapid
enzymatic hydrolysis to 6-monoacetylmorphine (6-MAM)
and morphine [40, 42, 43].
The experimental information obtained in this work
enables better understanding of the controversial biological
data reported for this type of cocaine–opioid system [2, 18,
21–23]. Pharmacological data clearly show that combina-
tion of cocaine with morphine produces an enhanced effect
relative that of each drug per se [2, 44] and/or may change
the toxicity profile of the isolated drugs [2, 45, 46]. There
is, in addition, clinical evidence (although arguable) of a
particular activity of the cocaine–morphine combination
(Brompton mixture) against chronic pain [47]. For the
cocaine–heroin mixture it was found that each drug act
largely per se. In fact, the combination of cocaine and
heroin is often described as synergistic [48], or responsible
for reinforcing and discriminative stimulus effects that are
similar to those of the drug alone [2, 18].
This work provides a new insight into cocaine–opioid
interactions at the molecular level. The development of
experimental methods combined with theoretical calcula-
tions has proved of utmost relevance to understanding the
molecular basis of drug–drug interactions. This type of study,
which clarifies the mechanisms of action of drugs of abuse,
may, hopefully, also lead to the development of effective
therapy, because no specific and reliable method for the
treatment co-drug abuse is yet available.
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